AAAAAA

   
Results: 1-11 |
Results: 11
TREATMENT OF PATIENTS WITH TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIAL TRACT WITH IFOSFAMIDE, PACLITAXEL, AND CISPLATIN - A PHASE-II TRIAL
Authors: BAJORIN DF MCCAFFREY JA HILTON S MAZUMDAR M KELLY WK SCHER HI SPICER J HERR H HIGGINS G
Citation: Df. Bajorin et al., TREATMENT OF PATIENTS WITH TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIAL TRACT WITH IFOSFAMIDE, PACLITAXEL, AND CISPLATIN - A PHASE-II TRIAL, Journal of clinical oncology, 16(8), 1998, pp. 2722-2727
RISK ASSESSMENT FOR METASTATIC TESTIS CANCER
Authors: MCCAFFREY JA BAJORIN DF MOTZER RJ
Citation: Ja. Mccaffrey et al., RISK ASSESSMENT FOR METASTATIC TESTIS CANCER, Urologic clinics of North America, 25(3), 1998, pp. 389
THERAPY FOR GOOD RISK GERM-CELL TUMORS
Authors: MCCAFFREY JA BAJORIN DF
Citation: Ja. Mccaffrey et Df. Bajorin, THERAPY FOR GOOD RISK GERM-CELL TUMORS, Seminars in oncology, 25(2), 1998, pp. 186-193
INTERSTITIAL PNEUMONITIS FOLLOWING BICALUTAMIDE TREATMENT FOR PROSTATE-CANCER
Authors: MCCAFFREY JA SCHER HI
Citation: Ja. Mccaffrey et Hi. Scher, INTERSTITIAL PNEUMONITIS FOLLOWING BICALUTAMIDE TREATMENT FOR PROSTATE-CANCER, The Journal of urology, 160(1), 1998, pp. 131-131
ANATOMIC SITE OF PRIMARY TRANSITIONAL-CELL CARCINOMA (TCC) DOES NOT AFFECT PROBABILITY OF RESPONSE TO M-VAC OR SURVIVAL
Authors: MCCAFFREY JA DODD PM HERR H VLAMIS V MAZUMDAR M HIGGINS G SCHER HI BAJORIN DF
Citation: Ja. Mccaffrey et al., ANATOMIC SITE OF PRIMARY TRANSITIONAL-CELL CARCINOMA (TCC) DOES NOT AFFECT PROBABILITY OF RESPONSE TO M-VAC OR SURVIVAL, The Journal of urology, 159(5), 1998, pp. 634-634
POSTCHEMOTHERAPY SURGERY AFTER M-VAC IN PATIENTS (PTS) WITH METASTATIC TRANSITIONAL-CELL CARCINOMA (TCC) CAN RESULT IN LONG-TERM SURVIVAL
Authors: DODD PM MCCAFFREY JA HERR H VLAMIS V MAZUMDAR M HIGGINS G SCHER HI BAJORIN DF
Citation: Pm. Dodd et al., POSTCHEMOTHERAPY SURGERY AFTER M-VAC IN PATIENTS (PTS) WITH METASTATIC TRANSITIONAL-CELL CARCINOMA (TCC) CAN RESULT IN LONG-TERM SURVIVAL, The Journal of urology, 159(5), 1998, pp. 636-636
CASODEX - DEFINING THE ROLE OF ANTIANDROGENS
Authors: MCCAFFREY JA SCHER HI
Citation: Ja. Mccaffrey et Hi. Scher, CASODEX - DEFINING THE ROLE OF ANTIANDROGENS, The cancer journal from Scientific American, 3(4), 1997, pp. 204-208
IFOSFAMIDE-CONTAINING AND CISPLATIN-CONTAINING CHEMOTHERAPY AS FIRST-LINE SALVAGE THERAPY IN GERM-CELL TUMORS - RESPONSE AND SURVIVAL
Authors: MCCAFFREY JA MAZUMDAR M BAJORIN DF BOSL GJ VLAMIS V MOTZER RJ
Citation: Ja. Mccaffrey et al., IFOSFAMIDE-CONTAINING AND CISPLATIN-CONTAINING CHEMOTHERAPY AS FIRST-LINE SALVAGE THERAPY IN GERM-CELL TUMORS - RESPONSE AND SURVIVAL, Journal of clinical oncology, 15(7), 1997, pp. 2559-2563
PHASE-II RANDOMIZED TRIAL OF GALLIUM NITRATE PLUS FLUOROURACIL VERSUSMETHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN IN PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA
Authors: MCCAFFREY JA HILTON S MAZUMDAR M SADAN S HEINEMAN M HIRSCH J KELLY WK SCHER HI BAJORIN DF
Citation: Ja. Mccaffrey et al., PHASE-II RANDOMIZED TRIAL OF GALLIUM NITRATE PLUS FLUOROURACIL VERSUSMETHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN IN PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA, Journal of clinical oncology, 15(6), 1997, pp. 2449-2455
PHASE-II TRIAL OF DOCETAXEL IN PATIENTS WITH ADVANCED OR METASTATIC TRANSITIONAL-CELL CARCINOMA
Authors: MCCAFFREY JA HILTON S MAZUMDAR M SADAN S KELLY WK SCHER HI BAJORIN DF
Citation: Ja. Mccaffrey et al., PHASE-II TRIAL OF DOCETAXEL IN PATIENTS WITH ADVANCED OR METASTATIC TRANSITIONAL-CELL CARCINOMA, Journal of clinical oncology, 15(5), 1997, pp. 1853-1857
WHAT IS THE ROLE OF NEPHRECTOMY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA - REPLY
Authors: MCCAFFREY JA MOTZER RJ
Citation: Ja. Mccaffrey et Rj. Motzer, WHAT IS THE ROLE OF NEPHRECTOMY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA - REPLY, Seminars in oncology, 23(1), 1996, pp. 19-21
Risultati: 1-11 |